Piramal starts phase-II clinical trials of diabetes drug

Piramal Life Sciences said it has started phase-II clinical trials of a molecule, aimed at treating diabetes, in Europe and India.

The company initiated the phase-II study of 'P1736-05', an insulin sensitising compound, which is being developed for the treatment of type-2 diabetes in India and Europe, Piramal Life Sciences said in a filing to the Bombay Stock Exchange (BSE).

P1736-05 is likely to provide a safe and effective therapeutic option to type-2 diabetic patients. While, the company has been granted an approval by Indian regulatory authorities, in Europe various EU regulatory authorities have granted an approval for conducting the trials, it added.

According to the World Health Organisation (WHO), Type-2 Diabetes Melitus is an emerging worldwide health crisis with an incidence rate of 300 million by 2025. Type-2 Diabetes Melitus or non-insulin dependent diabetes accounts for about 95% of the diabetic population.

On Monday, Piramal Life Sciences shares ended 5% higher at Rs191 on the BSE, while the benchmark Sensex gained 1.6% to 19,906 points.

User

Commodity Focus

Copper prices have been strong on encouraging economic data and falling inventories. On 2nd...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
Commodity Trends

Onions

The export price for onions has been increased by $55 to $275 a tonne for September, in...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)